Key result
Japanese IHD costs are projected to fall ~29% by 2029 from 2014 levels.
Observational
The economic burden of ischemic heart disease in Japan increased from 1996 to 2014 but is projected to decrease by 2029 due to a declining number of deaths and mortality costs despite an aging population.
Projected IHD cost decline may inform Japanese resource planning; leaves open prospective validation of forecasts.
BACKGROUND: Ischemic heart disease (IHD/ICD10: I20-I25) is the second leading cause of deaths in Japan and accounts for 40% of deaths due to heart diseases. This study aimed to calculate the economic burden of IHD using the cost of illness (COI) method and to identify key factors that drive the change of the economic burden of IHD. METHODS: We calculated the cost of illness (COI) every 3 years from 1996 to 2014 using governmental statistics. We then predicted the COI for every 3 years starting from 2017 up to 2029 using the fixed and variable model estimations. Only the estimated future population was used as a variable in the fixed model estimation. By contrast, variable model estimation considered the time trend of health-related indicators over the past 18 years. We derived the COI from the sum of direct and indirect costs (morbidity and mortality). RESULTS: The past estimation of COI slightly increased from 1493.8 billion yen in 1996 to 1708.3 billion yen in 2014. Future forecasts indicated that it would decrease from 1619.0 billion yen in 2017 to 1220.5 billion yen in 2029. CONCLUSION: The past estimation showed that the COI of IHD increased; in the mixed model, the COI was predicted to decrease with the continuing trend of health-related indicators. The COI of IHD in the future projection showed that, although the average age of death increased by social aging, the influence of the number of deaths and mortality cost decreased.
No takes yet. Share an insight, caveat, or question.
Gochi et al. (2018) conducted an observational in Ischemic heart disease. The cost of illness for ischemic heart disease in Japan increased from 1493.8 billion yen in 1996 to 1708.3 billion yen in 2014, but is projected to decrease to 1220.5 billion yen by 2029.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: